Bio-Techne Corporation (TECH)
Largest Insider Buys in Sector
TECH Stock Price History Chart
TECH Stock Performance
About Bio-Techne Corporation
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. It offers its products under R&D Systems, Tocris Biosciences, Novus Biologicals, ProteinSimple, Advanced Cell Diagnostics, Exosome Diagnostics, and Asuragen brands. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.
Insider Activity of Bio-Techne Corporation
Over the last 12 months, insiders at Bio-Techne Corporation have bought $0 and sold $2.29M worth of Bio-Techne Corporation stock.
On average, over the past 5 years, insiders at Bio-Techne Corporation have bought $105,765 and sold $36.28M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 300 shares for transaction amount of $105,765 was made by BAUMGARTNER ROBERT V () on 2022‑05‑10.
List of Insider Buy and Sell Transactions, Bio-Techne Corporation
| 2024-08-08 | Sale | director | 16,000 0.0099% | $72.10 | $1.15M | +1.20% | ||
| 2024-05-14 | Sale | director | 4,000 0.0025% | $83.84 | $335,377 | -10.99% | ||
| 2024-03-07 | Sale | director | 10,400 0.0066% | $76.98 | $800,627 | -3.21% | ||
| 2023-08-30 | Sale | director | 8,939 0.0057% | $80.32 | $717,959 | -10.75% | ||
| 2023-07-21 | Sale | Chief Executive Officer | 80,000 0.0503% | $88.36 | $7.07M | -19.60% | ||
| 2023-06-07 | Sale | Chief Executive Officer | 322 0.0002% | $83.00 | $26,726 | -12.11% | ||
| 2022-12-08 | Sale | SVP - GENERAL COUNSEL | 7,450 0.0048% | $82.12 | $611,810 | -4.32% | ||
| 2022-08-10 | Sale | 100 0.0003% | $374.89 | $37,490 | -14.58% | |||
| 2022-06-07 | Sale | CHIEF EXECUTIVE OFFICER | 5,104 0.013% | $365.00 | $1.86M | -10.27% | ||
| 2022-06-07 | Sale | 1,000 0.0025% | $364.31 | $364,310 | -10.27% | |||
| 2022-05-10 | 300 0.0008% | $352.55 | $105,765 | -6.24% | ||||
| 2021-11-19 | Sale | Pres. Diagnostics & Genom | 500 0.0013% | $505.38 | $252,689 | -25.89% | ||
| 2021-11-12 | Sale | President-Protein Sciences | 27,159 0.069% | $504.00 | $13.69M | -25.51% | ||
| 2021-11-02 | Sale | Chief Financial Officer | 200 0.0005% | $525.10 | $105,020 | -24.34% | ||
| 2021-11-01 | Sale | Chief Financial Officer | 8,822 0.0225% | $526.52 | $4.64M | -27.41% | ||
| 2021-10-29 | Sale | Chief Financial Officer | 662 0.0017% | $525.23 | $347,704 | -27.12% | ||
| 2021-10-28 | Sale | Chief Financial Officer | 100 0.0003% | $525.18 | $52,518 | -25.88% | ||
| 2021-09-22 | Sale | Pres. Diagnostics & Genom | 822 0.0021% | $529.04 | $434,871 | -24.44% | ||
| 2021-09-07 | Sale | director | 8,000 0.0203% | $509.98 | $4.08M | -19.57% | ||
| 2021-09-02 | Sale | Chief Financial Officer | 10,000 0.0254% | $507.22 | $5.07M | -18.94% |
Insider Historical Profitability
| BAUMGARTNER ROBERT V | director | 43401 0.0273% | $76.26 | 6 | 15 | +12.2% |
| Nusse Roeland | director | 43097 0.0271% | $76.26 | 0 | 5 | |
| HIGGINS JOHN L | director | 36608 0.023% | $76.26 | 0 | 8 | |
| Kummeth Charles R. | Chief Executive Officer | 1258766 0.7922% | $76.26 | 1 | 21 | +18.28% |
| OLAND THOMAS E | President | 1189420 0.7486% | $76.26 | 0 | 8 | |
| OCONNELL HOWARD V | director | 70000 0.0441% | $76.26 | 1 | 15 | +32.95% |
| VERONNEAU MARCEL | VP Hematology Operations | 34569 0.0218% | $76.26 | 0 | 5 | |
| Furlow Brenda S. | SVP - GENERAL COUNSEL | 26092 0.0164% | $76.26 | 0 | 10 | |
| Hippel James | Chief Financial Officer | 10755 0.0068% | $76.26 | 0 | 19 | |
| Dinarello Charles A | director | 8212 0.0052% | $76.26 | 0 | 6 | |
| STEER RANDOLPH C | director | 5112 0.0032% | $76.26 | 0 | 11 | |
| WIENS HAROLD J | director | 4843 0.003% | $76.26 | 0 | 4 | |
| WEATHERBEE JAMES A | Chief Scientific Officer | 3611 0.0023% | $76.26 | 0 | 2 | |
| Seth Alpna | director | 2139 0.0013% | $76.26 | 0 | 1 | |
| LUCAS ROGER C | director | 1870 0.0012% | $76.26 | 0 | 31 | |
| Gould Kevin S | SVP Clinical Controls | 1667 0.001% | $76.26 | 0 | 1 | |
| Eansor Norman David | President-Protein Sciences | 1318 0.0008% | $76.26 | 0 | 10 | |
| HOLBROOK KAREN A | director | 914 0.0006% | $76.26 | 0 | 6 | |
| HERBERT G A | director | 0 0% | $76.26 | 0 | 5 | |
| TSANG MONICA | VP of Research | 0 0% | $76.26 | 0 | 7 | |
| HENNEY CHRISTOPHER S | director | 0 0% | $76.26 | 0 | 5 | |
| REAGAN KEVIN J | Senior VP - Biotech | 0 0% | $76.26 | 0 | 2 | |
| Kelderman Kim | Pres. Diagnostics & Genom | 0 0% | $76.26 | 0 | 5 |
Institutional Investor Ownership
| The Vanguard Group | $1.29B | 11.6 | 18.27M | +0.24% | +$3.11M | 0.02 | |
| BlackRock | $1.25B | 11.26 | 17.75M | -2.14% | -$27.31M | 0.03 | |
| State Street | $448.31M | 4.04 | 6.37M | +0.64% | +$2.87M | 0.02 | |
| T. Rowe Price | $404.47M | 3.65 | 5.75M | +92.11% | +$193.93M | 0.05 | |
| Bamco | $351.82M | 3.17 | 5M | -6.61% | -$24.9M | 0.94 | |
| Morgan Stanley | $294.95M | 2.66 | 4.19M | +2.5% | +$7.19M | 0.02 | |
| Geode Capital Management | $269.48M | 2.44 | 3.84M | +3.13% | +$8.18M | 0.02 | |
| Neuberger Berman | $251.63M | 2.27 | 3.57M | -3.19% | -$8.3M | 0.21 | |
| Df Dent Co Inc | $239.11M | 2.16 | 3.4M | +4.81% | +$10.97M | 2.92 | |
| Ameriprise Financial | $230.95M | 2.08 | 3.28M | +62.29% | +$88.65M | 0.06 | |
| Invesco | $220.09M | 1.98 | 3.13M | +5.07% | +$10.62M | 0.05 | |
| Select Equity Group, L.P. | $211.93M | 1.91 | 3.01M | -33.96% | -$108.99M | 0.77 | |
| Mairs & Power, Inc. | $208.31M | 1.88 | 2.96M | -3.9% | -$8.46M | 2.02 | |
| BNY Mellon | $201.49M | 1.82 | 2.86M | +14.01% | +$24.75M | 0.04 | |
| Champlain Investment Partners, LLC | $193.2M | 1.74 | 2.74M | -1.13% | -$2.21M | 1.11 | |
| Mackenzie Financial Corp | $186.27M | 1.68 | 2.65M | +10.29% | +$17.38M | 0.25 | |
| Brown Capital Management | $180.7M | 1.63 | 2.57M | -27.7% | -$69.25M | 3.21 | |
| Macquarie Group | $178.35M | 1.61 | 2.53M | +0.87% | +$1.53M | 0.16 | |
| Massachusetts Financial Services Co Ma | $176.08M | 1.59 | 2.5M | +218.85% | +$120.86M | 0.05 | |
| William Blair Investment Management | $152.9M | 1.38 | 2.17M | -2.81% | -$4.42M | 0.4 | |
| Marshall Wace | $147.26M | 1.33 | 2.09M | -8.72% | -$14.07M | 0.15 | |
| Wellington Management Company | $134.47M | 1.21 | 1.91M | -2.26% | -$3.11M | 0.02 | |
| Northern Trust | $108M | 0.97 | 1.53M | -3.96% | -$4.45M | 0.02 | |
| Charles Schwab | $103.36M | 0.93 | 1.47M | +1.98% | +$2.01M | 0.02 | |
| Sumitomo Mitsui Trust Holdings | $100.27M | 0.9 | 1.42M | -1.16% | -$1.18M | 0.07 | |
| American Century Investments | $99.25M | 0.9 | 1.41M | +0.04% | +$42,797.12 | 0.06 | |
| Ownership Capital | $90.93M | 0.82 | 1.29M | -7.42% | -$7.29M | 2.08 | |
| Allspring Global Investments | $90.67M | 0.82 | 1.29M | -1.61% | -$1.49M | 0.14 | |
| Arrowmark Colorado Holdings Llc | $87.6M | 0.79 | 1.24M | +5.19% | +$4.32M | 0.22 | |
| Millennium Management LLC | $80.91M | 0.73 | 1.15M | +28,752.53% | +$80.63M | 0.05 | |
| Fidelity Investments | $77.99M | 0.7 | 1.11M | -6.9% | -$5.78M | 0.01 | |
| Geneva Capital Management LLC | $76.02M | 0.69 | 1.08M | +0.07% | +$53,285.22 | 1.34 | |
| Jackson Square LLC | $75.75M | 0.68 | 1.08M | -28.12% | -$29.63M | 3.26 | |
| ClearBridge Investments | $74.45M | 0.67 | 1.06M | -0.98% | -$739,517.19 | 0.06 | |
| Brown Advisory | $73.04M | 0.66 | 1.04M | +28.16% | +$16.05M | 0.1 | |
| Right Side Capital Management | $71.98M | 0.65 | 1.02M | +5.97% | +$4.06M | 1.54 | |
| American Capital Management, Inc. | $71.56M | 0.65 | 1.02M | +5.88% | +$3.97M | 2.29 | |
| HERITAGE ASSET MANAGEMENT INC | $70.18M | 0.64 | 1.01M | +8.56% | +$5.53M | 0.36 | |
| Janus Henderson | $70.1M | 0.63 | 995,824 | +1.32% | +$914,428.74 | 0.04 | |
| Legal & General | $69.04M | 0.62 | 980,842 | -2.82% | -$2M | 0.02 | |
| Alyeska Investment Group L P | $64.16M | 0.58 | 911,526 | +0.74% | +$471,894.56 | 0.4 | |
| Riverbridge Partners | $60.65M | 0.55 | 861,631 | -0.64% | -$391,931.62 | 0.75 | |
| Dimensional Fund Advisors | $57.56M | 0.52 | 817,711 | +11.39% | +$5.89M | 0.02 | |
| Alger | $57.59M | 0.52 | 818,124 | -12.23% | -$8.02M | 0.29 | |
| SEI Investments Company | $56.26M | 0.51 | 799,232 | -6.69% | -$4.03M | 0.08 | |
| ROYCE & ASSOCIATES INC | $56.07M | 0.51 | 796,564 | +16.55% | +$7.96M | 0.5 | |
| Goldman Sachs | $53.07M | 0.48 | 753,894 | +2.66% | +$1.38M | 0.01 | |
| Aristotle Atlantic Partners LLC | $51.79M | 0.47 | 735,759 | -3.12% | -$1.67M | 1.69 | |
| JPMorgan Chase | $50.8M | 0.46 | 721,760 | +28.23% | +$11.18M | 0.01 | |
| Sandhill Capital Partners Llc | $49.22M | 0.44 | 699,282 | +1.24% | +$604,157.25 | 3.94 |